Key Takeaways: A new American Heart Association analysis of 9,248 women published May 13, 2026 in the Journal of the American Heart Association found that perimenopausal women are twice as likely to have low cardiovascular health scores as premenopausal women, driven primarily by worsening cholesterol (76% higher risk of low cholesterol score) and blood sugar (83% higher risk of low score). Median Life's Essential 8 scores fell from 73.3 (premenopausal) to 69.1 (perimenopausal) to 63.9 (postmenopausal). The authors describe perimenopause as a "window of opportunity" -- the time to assess and intervene, not wait until postmenopause when damage has accumulated. For midlife women this means screening blood pressure, lipids, glucose, and hormones during the transition, prioritizing resistance training and a DASH-pattern diet, and considering hormone therapy within the early-start window when symptoms warrant it.
A New Study Reframes Perimenopause as a Cardiovascular Event
On May 13, 2026, researchers at the University of Alabama at Birmingham published a nationwide analysis in the Journal of the American Heart Association showing that cardiovascular health begins deteriorating in perimenopause -- well before menopause is reached -- and the decline is large enough to detect on a population-level cardiovascular health score [1].
The analysis used the National Health and Nutrition Examination Survey (NHANES) data from 2007 to 2020 and grouped 9,248 women into three reproductive stages: 5,882 premenopausal (median age 34), 205 perimenopausal (median age 50.5), and 3,161 postmenopausal (median age 60).
Each woman's cardiovascular health was scored using the American Heart Association's Life's Essential 8 (LE8) metric, which combines four lifestyle factors and four health biomarkers into a single 0-to-100 score:
Lifestyle factors:
Diet quality
Physical activity
Nicotine exposure
Sleep duration
Health biomarkers:
Body mass index
Blood lipids (non-HDL cholesterol)
Blood glucose
Blood pressure
The headline finding: median LE8 scores fell stepwise across reproductive stages from 73.3 in premenopausal women, to 69.1 in perimenopausal women, to 63.9 in postmenopausal women -- a near-10-point drop from premenopause to postmenopause, with roughly half of that decline already occurring by perimenopause.
After adjustment for age and other covariates, perimenopausal women were:
2 times more likely to have a low overall cardiovascular health score
76% more likely to have a low cholesterol score
83% more likely to have a low blood sugar score
compared to premenopausal women.
The senior author, Garima Arora, M.D., framed the takeaway directly: "Mid-life women should think of the perimenopausal period as a 'window of opportunity.' They should be proactive and not wait until they reach menopause to start checking their blood pressure, cholesterol and blood sugar levels."
Why the Cardiovascular System Changes in Perimenopause
The mechanism is the gradual loss of estradiol's vascular protective effects, compounded by the volatility of the hormonal transition.
Direct Vascular Effects
Estradiol acts on estrogen receptors in vascular endothelium to:
Increase nitric oxide production (vasodilation, lower blood pressure)
Suppress endothelin-1 (less vasoconstriction)
Reduce LDL accumulation in arterial walls
Decrease inflammatory cytokine production
Improve flow-mediated dilation
As estradiol becomes unpredictable in perimenopause and then drops through menopause, these protective effects erode. Endothelial function measurably worsens, and the rate of arterial stiffening accelerates compared to premenopausal years.
Lipid Metabolism
Estradiol shifts the liver toward HDL production and away from LDL retention. Loss of that signal during the transition produces the classic midlife lipid pattern: rising LDL, rising small-dense LDL particles, rising triglycerides, falling HDL. The 76% higher rate of low cholesterol scores in the AHA analysis is the population-level signal of this individual physiology.
Insulin Sensitivity and Visceral Fat
Estradiol promotes subcutaneous fat distribution and improves insulin signaling in muscle. As it falls, fat redistributes toward the visceral compartment, insulin resistance worsens, and fasting glucose drifts upward. This explains the 83% higher rate of low blood sugar scores -- it is not new diabetes appearing, it is the gradual metabolic shift that increases diabetes risk over the following decade.
Hot Flashes as Cardiovascular Events
A growing body of evidence treats hot flashes as cardiovascular stressors in their own right. During a hot flash, peripheral vessels dilate rapidly, heart rate rises 7 to 15 bpm, and systolic blood pressure transiently increases. Women with frequent or severe vasomotor symptoms have higher rates of subclinical atherosclerosis, even after adjustment for traditional risk factors.
Perimenopausal sleep fragmentation feeds directly into cardiovascular risk. Each hour of nightly sleep below 7 hours raises blood pressure and worsens glucose tolerance. The sleep disruption is bidirectional -- estradiol withdrawal causes sleep problems, and the resulting poor sleep then worsens metabolic and vascular health.
What Should Be Measured During the Window
The AHA analysis is a call to act on numbers, not symptoms alone. For women entering or in perimenopause, a baseline assessment should capture:
Lipid Panel With Particle Markers
Total cholesterol, LDL, HDL, triglycerides (standard)
ApoB -- the strongest single lipoprotein marker of atherosclerotic risk
Lp(a) -- once-in-a-lifetime test; if elevated, intensifies prevention urgency
Calculate non-HDL cholesterol (the LE8 lipid component)
Glucose and Insulin Resistance
Fasting glucose
HbA1c (3-month integrated average)
Fasting insulin (with glucose, calculate HOMA-IR)
Consider a 75-g oral glucose tolerance test if HbA1c is borderline
Blood Pressure
Office BP is unreliable in this age group due to white-coat reactivity
24-hour ambulatory monitoring or two weeks of home BP readings (twice daily, both arms)
Capture nocturnal dipping if possible -- non-dipping is a strong cardiovascular risk marker in women
Body Composition
BMI is the LE8 component but is insensitive in this age group
Waist circumference (more useful for visceral fat estimation)
DXA scan if available -- captures lean mass, fat distribution, and bone density in one study
Hormonal Panel
FSH (elevated FSH is the laboratory signature of perimenopause)
Estradiol (day 3 if still cycling; baseline if not)
Coronary artery calcium (CAC) score -- a low-radiation CT that directly measures plaque. In women 40 to 60 with any lipid or BP abnormality, this is the single most useful imaging study. A CAC of 0 reassures; any positive score escalates prevention intensity.
Women's HRT — Menopause-First Telehealth
Bioidentical estradiol, progesterone, and low-dose testosterone — all 50 states, unlimited physician access.
The AHA study itself did not assess hormone therapy as an intervention -- the authors noted that HRT data in NHANES was incomplete. But the cardiovascular literature on HRT timing is now reasonably mature.
The Timing Hypothesis
The 2017 Cochrane review of hormone therapy and cardiovascular outcomes found that women who started HRT within 10 years of menopause or before age 60 had:
Reduced all-cause mortality
Reduced coronary heart disease events
No increase in stroke for transdermal estradiol
Women who started HRT 10 or more years after menopause did not show the same benefit, and in some analyses showed modestly increased risk -- consistent with estrogen acting beneficially on healthy endothelium but destabilizing already-formed plaque.
The biological logic: vascular tissue rich in estrogen receptors that has spent decades in a normal estrogen environment responds to replacement therapy by maintaining function. Vascular tissue that has been estrogen-deprived for 10+ years has remodeled and developed plaque, and the response to estrogen reintroduction is different.
For cardiovascular risk specifically, transdermal estradiol is preferred:
Avoids first-pass hepatic effects that raise SHBG, CRP, and clotting factors
Lower thromboembolic risk than oral
More stable serum levels
Compatible with women who have lipid abnormalities or hypertension
Oral conjugated estrogens were the formulation used in the original Women's Health Initiative trials, which produced the cardiovascular signals that drove the now-removed black box warnings. Modern transdermal estradiol has a different safety profile. For the regulatory backstory, see HRT Black Box Warning Removed.
Progesterone Choice
For women with an intact uterus, progesterone is required for endometrial protection. The choice between micronized progesterone and synthetic progestins has cardiovascular implications:
Micronized progesterone: Cardiovascular-neutral; some evidence of mild blood pressure-lowering and sleep benefit
Medroxyprogesterone acetate: The progestin used in WHI; associated with worse cardiovascular and lipid outcomes
Norethindrone, drospirenone, others: Mixed profiles depending on the specific molecule
Body-identical micronized progesterone is the cardiovascular-friendlier choice when HRT is initiated for symptom relief plus the bonus of metabolic and vascular benefit.
When HRT Is Not the Cardiovascular Answer
HRT is not currently recommended as a standalone cardiovascular prevention therapy by any major society. It is recommended for vasomotor symptoms, genitourinary syndrome, bone protection, and quality of life, and the cardiovascular benefit is layered on when treatment falls within the timing window. Women with:
No perimenopausal symptoms
Personal history of estrogen-sensitive breast cancer
Active thromboembolic disease
Severe untreated hypertension or coronary disease
should not receive HRT for cardiovascular prevention. Standard prevention -- statins, antihypertensives, lifestyle -- remains the evidence-based path.
What the LE8 Components Demand in Daily Life
The eight LE8 factors are all modifiable, and the AHA analysis shows that midlife women lose ground on several simultaneously. Practical priorities in order of effect size for this age group:
Resistance Training (2 to 4 Sessions Weekly)
This is the single highest-yield intervention for perimenopausal women:
Preserves and rebuilds lean mass that estradiol loss accelerates
Improves insulin sensitivity in muscle (the largest glucose disposal site)
Raises HDL cholesterol (one of the few interventions that does)
Maintains resting metabolic rate that otherwise drops by 100 to 200 kcal/day across the transition
Preserves bone density alongside cardiovascular benefit
Combine compound lifts (squat, deadlift, row, press variants) with progressive overload. Cardio is good; resistance training is better for this physiology.
DASH or Mediterranean-Pattern Diet With Sodium Control
Target sodium under 2,300 mg/day, ideally 1,500 mg/day if blood pressure is elevated
This pattern drops systolic blood pressure 5 to 10 mmHg in midlife women -- equivalent to a single antihypertensive medication
Sleep Regularization
Target 7 to 9 hours nightly
Treat sleep apnea if present (prevalence rises sharply at menopause)
Hot flashes that disrupt sleep are an HRT indication, not "just life"
The cardiovascular cost of chronic short sleep in this window is large
Nicotine Cessation
Smoking accelerates cardiovascular damage faster than any other modifiable factor in midlife women
E-cigarettes have not been shown to be cardiovascular-safe
Nicotine vapes still drive vasoconstriction and endothelial dysfunction
Alcohol Under 7 Drinks per Week
Alcohol disrupts sleep architecture (less REM, more night waking)
Raises blood pressure
Worsens hot flashes
Provides empty calories that displace nutrient density
Where Testosterone Fits
Female testosterone is a smaller but not zero piece of the perimenopausal cardiovascular picture.
Total testosterone in women declines steadily from the late 20s, with free testosterone often hitting its lowest values as SHBG rises in perimenopause
Low testosterone in women correlates with lower lean mass, reduced exercise tolerance, worse insulin sensitivity
A 2024 systematic review of testosterone therapy in postmenopausal women found no cardiovascular harm signal and modest metabolic improvement at physiologic female doses
The randomized trial evidence is strongest for sexual function, not cardiovascular outcomes
Concrete action items distilled from the AHA recommendations:
Order a baseline lipid panel with ApoB (and Lp(a) if never done). Fasting is not strictly required for ApoB but improves precision of triglycerides.
Order HbA1c and fasting glucose. If HbA1c is 5.7% to 6.4%, you are in pre-diabetes territory and the window for reversal is open.
Two weeks of home blood pressure readings (twice daily, both arms, seated, after 5 min rest). Average them. Anything over 130/80 deserves attention.
Order an FSH and estradiol if you suspect perimenopause but have not been formally evaluated.
Start two resistance training sessions per week if not already lifting. This is the single most evidence-supported behavioral change for this window.
Cut alcohol to under 4 to 7 drinks per week. This alone improves sleep, blood pressure, and hot flashes.
If you have moderate-to-severe perimenopausal symptoms, book a consultation with a clinician who handles HRT. The timing window for cardiovascular benefit closes around 10 years post-menopause; starting in perimenopause keeps it open.
For comprehensive hormonal evaluation and HRT initiation, Compare All Clinics lists clinics scored for diagnostic depth and physician quality, which matter most when the goal is both symptom relief and long-term cardiovascular and metabolic optimization.
What This Study Adds to the 2026 Picture
The Nayak and Arora analysis is not the first to identify perimenopause as a cardiovascular pivot. The American Heart Association issued a Scientific Statement in 2020 specifically on the menopause transition and CVD risk [2]. What this 2026 paper adds is a quantitative LE8-based snapshot of how much cardiovascular health has already eroded by the time women reach perimenopause, on a population that includes more than 9,000 women followed through nationally representative health surveys.
The practical implication for clinical practice: cardiovascular screening that has traditionally started at menopause -- when many of these changes are already established -- should start at perimenopause, when there is still room to bend the curve.
Nayak A, Arora G, et al. Cardiovascular Health Across the Menopause Transition: A National Cross-Sectional Analysis Using Life's Essential 8. Journal of the American Heart Association. Published online May 13, 2026. AHA Newsroom Press Release
El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020;142(25):e506-e532. PMID: 33251828
Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;(3):CD002229. PMID: 25754617
Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association. Circulation. 2022;146(5):e18-e43. PMID: 35766027
Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017;318(10):927-938. PMID: 28898378
Thurston RC, Aslanidou Vlachos HE, Derby CA, et al. Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN. J Am Heart Assoc. 2021;10(3):e017416. PMID: 33470142
Frequently Asked Questions
Why does cardiovascular health drop in perimenopause specifically?
Estradiol is a vascular protective hormone: it relaxes arteries via nitric oxide, suppresses LDL accumulation, improves insulin sensitivity, and reduces visceral fat. As estradiol becomes erratic in perimenopause and then declines through menopause, those protective effects erode. The AHA analysis showed cholesterol scores were 76% more likely to be low and blood sugar scores 83% more likely to be low in perimenopausal women compared to premenopausal women -- two of the largest drivers of long-term heart disease risk. Hot flashes themselves are now considered cardiovascular events, with transient blood pressure spikes and altered heart rate variability.
What does Life's Essential 8 mean and why is it the new standard?
Life's Essential 8 (LE8) is the American Heart Association's 2022 update to its cardiovascular health metric. It scores eight factors on a 0 to 100 scale: four lifestyle behaviors (diet, physical activity, nicotine exposure, sleep) and four health markers (BMI, blood lipids, blood glucose, blood pressure). The AHA study used LE8 because it captures both modifiable habits and biomarkers in a single composite score, allowing direct comparison across reproductive stages. The median score fell from 73.3 in premenopausal women to 69.1 in perimenopausal to 63.9 in postmenopausal women in this analysis.
If I am in perimenopause, what should I test right now?
The minimum panel is fasting lipid panel (total cholesterol, LDL, HDL, triglycerides, ideally with ApoB and Lp(a) on the first run), HbA1c plus fasting glucose, a 24-hour ambulatory or repeated home blood pressure measurement, and a hormone panel (FSH, estradiol, free and total testosterone, SHBG, progesterone if still cycling). A high-sensitivity CRP gives a residual inflammatory risk read. If you are over 40 with any abnormality on lipids or glucose, a coronary artery calcium score is a low-cost imaging study that quantifies actual plaque burden. Repeat the metabolic and lipid panels annually through the transition.
Does hormone therapy actually lower heart disease risk?
The evidence supports a window-of-opportunity benefit, not a universal one. The 2017 Cochrane review of hormone therapy and cardiovascular outcomes found that women who started hormone therapy within 10 years of menopause or before age 60 had reduced all-cause mortality and coronary heart disease compared to placebo. Started 10+ years out, the same therapy showed neutral or modestly harmful cardiovascular signals. This is the timing hypothesis: estrogen acts on healthy endothelium to maintain vascular function, but on already-plaqued arteries it can destabilize plaque. The perimenopausal and early postmenopausal years are the window where the cardiovascular benefit appears.
Should I start HRT just for heart disease prevention?
No major guideline body, including the American Heart Association and the Menopause Society, currently recommends HRT for primary cardiovascular prevention as a standalone indication. The benefit is real but is layered: HRT is recommended for vasomotor symptoms, genitourinary syndrome of menopause, bone protection, and quality of life, and the cardiovascular and metabolic benefit comes along with it when treatment is started in the timing window. If you have moderate-to-severe perimenopausal symptoms, the cardiovascular benefit is an additional reason to start in the window. If you have no symptoms and a strong family history of heart disease, statin therapy, lifestyle, and blood pressure control remain the evidence-based first line.
What lifestyle changes have the largest LE8 impact during this window?
In order of effect size for perimenopausal women: 1) Resistance training 2 to 4 sessions weekly (raises HDL, improves insulin sensitivity, preserves lean mass that maintains resting metabolic rate); 2) DASH or Mediterranean-pattern diet with sodium under 2,300 mg/day (drops systolic blood pressure 5 to 10 mmHg in this age group); 3) Sleep regularization 7 to 9 hours nightly (perimenopausal sleep disruption directly worsens glucose tolerance and blood pressure); 4) Stop nicotine entirely if applicable (smoking accelerates cardiovascular damage faster than any other modifiable factor in midlife women); 5) Alcohol under 7 drinks per week (alcohol disrupts sleep, raises blood pressure, and worsens hot flashes that themselves stress the cardiovascular system).
What about testosterone -- does low T contribute to women's heart risk in this window too?
Women's testosterone declines from the late 20s onward, and free testosterone is often lowest right around perimenopause when SHBG rises. Low testosterone in women correlates with lower lean mass, reduced exercise capacity, and worse insulin sensitivity -- all cardiovascular health inputs. There is no randomized trial of female testosterone replacement for cardiovascular outcomes specifically, but a 2024 systematic review of testosterone in postmenopausal women found no signal of cardiovascular harm and modest metabolic improvement at physiologic doses. Testosterone is typically added to estrogen therapy when energy, libido, or muscle loss are prominent, not started for cardiovascular reasons alone.
